Department of Endocrinology, the Second Hospital of Jilin University, Changchun 130041, Jilin, P.R. China.
Department of Nephrology, the Second Hospital of Jilin University, Changchun 130041, Jilin, P.R. China.
Int J Med Sci. 2023 Sep 11;20(11):1492-1507. doi: 10.7150/ijms.87472. eCollection 2023.
Diabetes mellitus and its complications pose a major threat to global health and affect the quality of life and life expectancy of patients. Currently, the application of traditional therapeutic drugs for diabetes mellitus has great limitations and can only temporarily control blood glucose but not fundamentally cure it. Mesenchymal stem cells, as pluripotent stromal cells, have multidirectional differentiation potential, high self-renewal, immune regulation, and low immunogenicity, which provide a new idea and possible development direction for diabetes mellitus treatment. Regenerative medicine with mesenchymal stem cells treatment as the core treatment will become another treatment option for diabetes mellitus after traditional treatment. Recently, human umbilical cord mesenchymal stem cells have been widely used in basic and clinical research on diabetes mellitus and its complications because of their abundance, low ethical controversy, low risk of infection, and high proliferation and differentiation ability. This paper reviews the therapeutic role and mechanism of human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications and highlights the challenges faced by the clinical application of human umbilical cord mesenchymal stem cells to provide a more theoretical basis for the application of human umbilical cord mesenchymal stem cells in diabetes mellitus patients.
糖尿病及其并发症对全球健康构成重大威胁，影响患者的生活质量和预期寿命。目前，糖尿病的传统治疗药物的应用有很大的局限性，只能暂时控制血糖，而不能从根本上治愈它。间充质干细胞作为多能基质细胞，具有多向分化潜能、高自我更新、免疫调节和低免疫原性，为糖尿病的治疗提供了新的思路和可能的发展方向。以间充质干细胞治疗为核心的再生医学将成为糖尿病传统治疗后的另一种治疗选择。最近，人脐带间充质干细胞因其丰富、低伦理争议、低感染风险、高增殖分化能力，已广泛应用于糖尿病及其并发症的基础和临床研究。本文综述了人脐带间充质干细胞在糖尿病及其并发症中的治疗作用及其机制，并强调了人脐带间充质干细胞临床应用所面临的挑战，为人脐带间充质干细胞在糖尿病患者中的应用提供了更充分的理论依据。
